Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Werner Poewe

Showing results (331-340 of 602) with videos related to

Pageof 61
Sort By:
Parkinsonism & Related Disorders|December 22, 2019
Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based studyPhilipp Mahlknecht, Heike Stockner, Kathrin Marini, et al.
Annals of Neurology|July 23, 2005
Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndromeChristoph Schmidauer, Martin Sojer, Klaus Seppi, et al.
Pharmacoeconomics - Open|October 31, 2025
Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology AssessmentTobias Sydendal Grand, Shijie Ren, Praveen Thokala, et al.
Neuro-Degenerative Diseases|May 22, 2013
Substantia nigra hyperechogenicity as a marker for Parkinson's disease: a population-based studyPhilipp Mahlknecht, Klaus Seppi, Heike Stockner, et al.
Brain Sciences|May 28, 2022
Eye Tracking in Patients with Parkinson's Disease Treated with Nabilone-Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot StudyPhilipp Ellmerer, Marina Peball, Federico Carbone, et al.
Parkinsonism & Related Disorders|January 30, 2025
Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND studyAaron L Ellenbogen, Werner Poewe, Alberto J Espay, et al.
Neurology and Therapy|June 15, 2022
Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON TrialJoaquim J Ferreira, Werner Poewe, Olivier Rascol, et al.
Journal of Parkinson'S Disease|November 19, 2023
Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover StudyFabrizio Stocchi, Olivier Rascol, Werner Poewe, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2022
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's DiseaseJoaquim J Ferreira, Werner Poewe, Olivier Rascol, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 25, 2017
Very late-onset pure autonomic failureAlessandra Fanciulli, Nadia Stefanova, Christoph Scherfler, et al.
Pageof 61

Showing results (331-340 of 602) with videos related to

Sort By:
Pageof 61
Parkinsonism & Related Disorders|December 22, 2019
Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based studyPhilipp Mahlknecht, Heike Stockner, Kathrin Marini, et al.
Annals of Neurology|July 23, 2005
Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndromeChristoph Schmidauer, Martin Sojer, Klaus Seppi, et al.
Pharmacoeconomics - Open|October 31, 2025
Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology AssessmentTobias Sydendal Grand, Shijie Ren, Praveen Thokala, et al.
Neuro-Degenerative Diseases|May 22, 2013
Substantia nigra hyperechogenicity as a marker for Parkinson's disease: a population-based studyPhilipp Mahlknecht, Klaus Seppi, Heike Stockner, et al.
Brain Sciences|May 28, 2022
Eye Tracking in Patients with Parkinson's Disease Treated with Nabilone-Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot StudyPhilipp Ellmerer, Marina Peball, Federico Carbone, et al.
Parkinsonism & Related Disorders|January 30, 2025
Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND studyAaron L Ellenbogen, Werner Poewe, Alberto J Espay, et al.
Neurology and Therapy|June 15, 2022
Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON TrialJoaquim J Ferreira, Werner Poewe, Olivier Rascol, et al.
Journal of Parkinson'S Disease|November 19, 2023
Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover StudyFabrizio Stocchi, Olivier Rascol, Werner Poewe, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2022
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's DiseaseJoaquim J Ferreira, Werner Poewe, Olivier Rascol, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 25, 2017
Very late-onset pure autonomic failureAlessandra Fanciulli, Nadia Stefanova, Christoph Scherfler, et al.
Pageof 61